REDO-JAK trial
In the REDO-JAK trial (Dose REDuction Of JAK inhibitors in patients with inflammatory rheumatic diseases) we investigate if a step-by-step dose reduction is feasible for JAK inhibitor users with low disease activity.
JAK inhibitors are used in the treatment of rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. While effective, they are costly and have side effects. Stepwise dose reduction has proven effective for other anti-rheumatic drugs. We will investigate if this also applies to JAK inhibitors. In this trial, 200 JAK inhibitor users with low disease activity will be monitored for one year. Part of this group will reduce their JAK inhibitor dose every three months until a flare occurs (leading to dose adjustment) or medication is stopped. Patients are guided by their rheumatologist. This approach aims to optimize JAK inhibitor use.
